What is ADVATE 250 IU
ADVATE 250 IU is a recombinant form of coagulation factor VIII, used for the treatment and prevention of bleeding episodes in individuals with Hemophilia A (congenital factor VIII deficiency). This product is not indicated for the treatment of von Willebrand disease.
- Generic Name: Octocog alfa (Recombinant human coagulation factor VIII)
- Form: Injection/Powder for reconstitution
- Packaging: 1 Vial (Powder) + 1 Solvent Vial (5ml) + Kit (2 Alcohol Swabs + 2 Dermaplasts + 1 Syringe + 1 Butterfly Infusion Set)
- Indication: Control and prevention of bleeding episodes, perioperative management, and routine prophylaxis in patients with Hemophilia A
ADVATE is produced by recombinant DNA technology, eliminating the risk of contamination with human blood-borne viruses. It is identical in structure to naturally occurring factor VIII but is free of human or animal-derived proteins.
How to use ADVATE 250 IU
ADVATE should be used strictly under the guidance and supervision of a healthcare professional experienced in treating hemophilia.
- Preparation:
- Wash hands thoroughly.
- Use aseptic technique throughout preparation and administration.
- Reconstitute the powder with the provided 5ml solvent vial using the transfer device.
- Gently swirl (do not shake) the vial until the powder is completely dissolved (clear solution).
- Administration:
- Inspect the solution for particulates or discoloration—do not use if cloudy or contains particles.
- Withdraw the solution into the provided syringe.
- Inject intravenously using the included butterfly infusion set, typically over 5 minutes or as directed by the physician.
- Frequency: Dosage and frequency depend on the patient’s weight, severity of factor VIII deficiency, and clinical situation (e.g., acute bleeding vs. prophylaxis).
Dispose of all used materials safely. Never reuse needles or syringes. Always keep a log of doses used and any reactions.
Mode of Action ADVATE 250 IU
ADVATE (Octocog alfa) works by replacing the missing or deficient clotting factor VIII in patients with Hemophilia A.
- Mechanism:
- Factor VIII plays a central role in the intrinsic pathway of the coagulation cascade.
- In normal physiology, when vascular injury occurs, factor VIII is activated (VIIIa) and serves as a cofactor for factor IXa to convert factor X to Xa, a key step in the generation of thrombin and the formation of a stable fibrin clot.
- In Hemophilia A patients, this process is impaired, resulting in prolonged bleeding.
- Effect of ADVATE:
- By supplying recombinant factor VIII, ADVATE temporarily restores hemostasis, enabling clot formation and preventing or controlling bleeding.
- It mimics the physiological activity of endogenous factor VIII, allowing proper blood coagulation.
Since ADVATE is recombinant, it eliminates risks associated with plasma-derived products, such as potential transmission of human pathogens.
ADVATE 250 IU Interactions ADVATE 250 IU
Although ADVATE is generally well-tolerated, caution must be exercised when it is administered with certain medications or in specific clinical settings.
- No known drug interactions: ADVATE has no established pharmacokinetic or pharmacodynamic interactions with commonly used drugs. However, since no specific interaction studies have been conducted, potential interactions cannot be ruled out entirely.
- Antibody interference:
- Development of neutralizing antibodies (inhibitors) to factor VIII is a known immunological reaction that can reduce the efficacy of the product.
- Patients with inhibitors may require bypassing agents such as activated prothrombin complex concentrates (aPCC) or recombinant factor VIIa, which are not used concurrently with ADVATE.
- Concurrent use in surgeries:
- In perioperative management, the use of antifibrinolytics like tranexamic acid or aminocaproic acid may be considered to improve hemostasis but should be monitored by the physician.
Always inform your healthcare provider of any other medicines, supplements, or herbal products being used before starting ADVATE therapy.
Dosage of ADVATE 250 IU
ADVATE dosage must be individualized according to the severity of the factor VIII deficiency, location and extent of bleeding, and the patient’s clinical condition.
Dosing recommendations may vary based on patient response, half-life of the product in individual patients, and clinical judgment.
Possible side effects of ADVATE 250 IU
ADVATE is generally well-tolerated, but like all medications, it may cause side effects in some individuals.
- Common Side Effects:
- Headache
- Nausea
- Fever (pyrexia)
- Injection site reactions (pain, redness, swelling)
- Less Common but Serious Side Effects:
- Allergic reactions such as rash, itching, urticaria
- Anaphylaxis (rare but potentially life-threatening)
- Development of neutralizing antibodies (inhibitors) to factor VIII
- Immunogenicity:
- Especially in previously untreated patients (PUPs), there’s a higher risk of developing inhibitors, which can reduce or negate the effect of the drug.
Seek immediate medical attention if symptoms of an allergic reaction (tightness of chest, swelling of lips/tongue, difficulty breathing) occur.
ADVATE 250 IU Contraindications ADVATE 250 IU
ADVATE is contraindicated in patients with specific conditions or known sensitivities. It should be avoided in the following scenarios:
- Hypersensitivity:
- Known allergy to Octocog alfa or any of the excipients in the formulation
- History of life-threatening hypersensitivity (e.g., anaphylaxis) to mouse or hamster proteins (used in the manufacturing process)
- Active inhibitors:
- Patients with high-titer factor VIII inhibitors may not respond adequately to treatment with ADVATE and should be treated with alternative therapies.
Use with caution in patients with known risk factors for thromboembolic events or those undergoing major surgery. Always assess individual risks before initiating therapy.
Storage of ADVATE 250 IU
Proper storage of ADVATE ensures stability, potency, and safety of the product before use.
- Temperature:
- Store ADVATE in a refrigerator at 2°C to 8°C (36°F to 46°F).
- May be stored at room temperature (up to 25°C or 77°F) for a single period of up to 6 months; record the start date if removed from the refrigerator.
- Protection:
- Keep the vials in the original carton to protect from light.
- Do not freeze. Freezing may damage the product and solvent.
- After reconstitution:
- Use immediately or within 3 hours if kept at room temperature.
- Do not refrigerate after reconstitution.
Keep out of reach of children and do not use beyond the expiration date printed on the packaging.
ADVATE 250 IU features an exceptional active ingredient renowned for its potent effects, comprising Octocog alfa (Coagulation factor VIII, recombinant). This powerful formulation provides a superior solution for addressing diverse health concerns. With 250 IU/Vial concentration and an easily manageable Injection/Powder for, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about ADVATE 250 IU .
Welcome to Dwaey, specifically on ADVATE 250 IU page.
This medicine contains an important and useful components, as it consists of Octocog alfa (Coagulation factor VIII, recombinant).
ADVATE 250 IU is available in the market in concentration 250 IU/Vial and in the form of Injection/Powder for.
TAKEDA MANUFACTURING AUSTRIA AG is the producer of ADVATE 250 IU and it is imported from AUSTRIA,
The most popular alternatives of ADVATE 250 IU are listed downward .
-
Active Substance
Octocog alfa (Coagulation factor VIII, recombinant)
-
Size
1 Vial (Powder) + 1 Solvent Vial (5ml) + Kit (2 Alcohol Swabs + 2 Dermaplasts + 1 Syringe + 1 Butterfly Infusion Set)
-
Indications
- No indications available.
-
Type
-
Company
TAKEDA MANUFACTURING AUSTRIA AG
Frequently Asked Questions
ADVATE 250 IU should be stored according to the instructions provided by TAKEDA MANUFACTURING AUSTRIA AG.
In general, it is recommended to store ADVATE 250 IU in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with ADVATE 250 IU may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking ADVATE 250 IU for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking ADVATE 250 IU . Some medications, including
ADVATE 250 IU , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of ADVATE 250 IU , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking ADVATE 250 IU without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking ADVATE 250 IU if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of ADVATE 250 IU during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 250 IU/Vial,
and the specific recommendations of TAKEDA MANUFACTURING AUSTRIA AG.
The effects of ADVATE 250 IU on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 250 IU/Vial, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking ADVATE 250 IU with or without food may vary depending on the medication
and the recommendations of TAKEDA MANUFACTURING AUSTRIA AG. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of ADVATE 250 IU in children or elderly individuals may depend on various factors, including
the specific medication, type Injection/Powder for, and the recommendations of TAKEDA MANUFACTURING AUSTRIA AG. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of ADVATE 250 IU in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments